EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection

Emily Alger iD, Sumithra J Mandrekar iD, Jun Yin, Christina Yap iD

Statistical Methods in Medical Research · 2026-06 · 35 (6) · 1177-1198

DOI: 10.1177/09622802261435969 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistical Methods in Medical Research, online erschienen am 29.04.2026. Verfasst von Emily Alger und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial and Statistics Unit, Institute of Cancer Research, UK. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Maximum Tolerated Dose, Dose-Response Relationship, Drug, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Institute of Cancer Research, London.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in oncology drug development are driving the emergence of novel therapies, challenging traditional dose-efficacy assumptions in dose-finding oncology trials. Traditional trial designs aim to identify a maximum tolerated dose (MTD) by assessing patients’ dose-limiting toxicities (DLTs) – adopting traditional dose-efficacy paradigms that efficacy increases with treatment dose. With these new therapies in mind, emphasis should shift toward methodological advancements in trial designs aimed at identifying optimal doses, rather than solely determining MTDs. Incorporating patient-reported outcomes (PROs) within dose-finding oncology trials is increasingly recommended to better understand treatments’ tolerability profiles, especially given the extended tolerability assessment windows for novel immunotherapies and targeted therapies. This article introduces PRO-ADD ( P atient- R eported O utcomes A ided D ose-optimisation D esign), a modular trial design framework for dose-optimisation. We leverage this framework to optimise dosage with respect to three key outcomes – clinician-assessed DLTs, PROs and preliminary efficacy. PRO-ADD performs well at identifying the optimal dose (both efficacious and tolerable) – successfully identifying the most tolerable effective dose and avoiding escalation to larger, safe doses offering no additional efficacy benefit. As the field evolves, patient-centric dose-finding approaches incorporating PROs are crucial in advancing our understanding of treatment tolerability, and in turn, shaping the future landscape of dose-finding oncology trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresMaximum Tolerated DoseDose-Response Relationship, DrugAntineoplastic AgentsClinical Trials as TopicHumansNeoplasmsResearch DesignTreatment Outcome

Stichwörter der Autor:innen

Patient-reported outcomesdose-finding trialsdose-optimisationoptimal biological dosephase I

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Clinical Trial and Statistics Unit, Institute of Cancer Research, UK.
  • Department of Quantitative Health Sciences, Mayo Clinic, USA.
  • Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, USA.

ORCID-Profile: Emily Alger, Sumithra J Mandrekar, Christina Yap

Förderung

  • The Institute of Cancer Research, London

Zitieren

APA

Alger, E., Mandrekar, S. J., Yin, J., & Yap, C. (2026). PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection. Statistical Methods in Medical Research, 35(6), 1177-1198. https://doi.org/10.1177/09622802261435969

Vancouver

Alger E, Mandrekar SJ, Yin J, Yap C. PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection. Statistical Methods in Medical Research. 2026;35(6):1177-1198. doi:10.1177/09622802261435969

BibTeX
@article{Alger2026,
  author = {Alger, Emily and Mandrekar, Sumithra J and Yin, Jun and Yap, Christina},
  title = {PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection},
  journal = {Statistical Methods in Medical Research},
  year = {2026},
  volume = {35},
  number = {6},
  pages = {1177--1198},
  doi = {10.1177/09622802261435969}
}
Kostenlos starten →